The effect of different doses of metamisole sodium on serum enzyme activities and tissue oxidant levels in liver and kidney in mice

被引:0
作者
Yapar, Kuersad [1 ]
Atakisi, Ernine [3 ]
Uzlu, Erdogan [2 ]
Atakisi, Onur [3 ]
Citil, Mehmet [2 ]
Uzun, Metehan [4 ]
Erdogan, Hidayet Metin [2 ]
机构
[1] Giresun Univ, Giresun, Turkey
[2] Kafkas Univ, Vet Fak, Ic Hastaliklari AD, Kars, Turkey
[3] Kafkas Univ, Vet Fak, Biyokimya AD, Kars, Turkey
[4] Kafkas Univ, Vet Fak, Fizyoloji AD, Kars, Turkey
关键词
metamisole sodium; enzyme; MDA; GSH; liver; kidney;
D O I
暂无
中图分类号
S85 [动物医学(兽医学)];
学科分类号
0906 ;
摘要
Metamisole sodium (MS), a pyrosilone derivate, is widely used non-opioid analgesic in veterinary medicine. This study evaluated the effect of different doses of metamisole sodium on serum urea, creatin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phophatase (ALP) activities and tissue malondialdehyde (MDA) and reduced glutathione (GSH) level in liver and kidney in mice. The study involved 32 Swiss Albino mice. Animals were divided into four equal groups. One group was left control the other three groups received 20 (Group 1), 50 (Group II) and 100 mg/kg (Group III) MS intramuscularly for 7 days. After a seven-day injection blood and tissue samples were collected from mice. Serum samples were examined for the determination of BUN, creatin, ALT, AST and ALP while tissue samples were evaluated for MDA and GSH levels. The high dose group (100 mg/kg) had higher concentrations of serum BUN, creatin, ALT, AST and tissue MDA but low concentration of GSH (p<0.05) when compared to other groups. In conclusion, short term high dose (100 mg/kg) of MS resulted in liver and kidney degeneration.
引用
收藏
页码:121 / 125
页数:5
相关论文
共 31 条
  • [1] BEUTLER E, 1963, J LAB CLIN MED, V61, P882
  • [2] Adverse gastrointestinal effects of NSAIDs: consequences and costs
    Bidaut-Russell, M
    Gabriel, SE
    [J]. BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY, 2001, 15 (05) : 739 - 753
  • [3] BJORKMAN D, 1998, AM J MED, V105, P17
  • [4] BOOTHE D. M., 1995, VET PHARM THERAPEUTI
  • [5] BROOKS PM, 1991, NEW ENGL J MED, V324, P1716
  • [6] BUSH TM, 1991, WESTERN J MED, V155, P39
  • [7] COLLINS AJ, 1986, BRIT J RHEUMATOL, V25, P50
  • [8] Inhibition of human neutrophil oxidative burst by pyrazolone derivatives
    Costa, D
    Marques, AP
    Reis, RL
    Lima, JLFC
    Fernandes, E
    [J]. FREE RADICAL BIOLOGY AND MEDICINE, 2006, 40 (04) : 632 - 640
  • [9] ERTEKIN A, 2001, YYU VET FAK DERG, V12, P105
  • [10] FRIES JF, 1991, ARTHRITIS RHEUM, V34, P1353